MedTrace Logo

Leukemic Stem Cell Detection for Chronic Myeloid Leukemia Patients With Major Molecular Response

NCT04104035 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2019-09-27

No results posted yet for this study

Summary

Multi-Center, national, non-drug, prospective cohort study Target patient number is 100 The amount of CD45+/CD34+/CD38-/CD26+ levels of chronic myeloid leukemia (CML) stem cells in CML patients with and without BCR-ABL hematopoiesis will be compared.

There will be 2 arms;

1. Patients with BCR-ABL-positive hematopoiesis
2. CML patients with BCR-ABL activity inhibition under tyrosine kinase inhibitor (TKI) therapy

Conditions

  • Chronic Myeloid Leukemia

Sponsors & Collaborators

  • Ankara University

    lead OTHER

Principal Investigators

  • Osman Ilhan, Prof · Ankara University Medical Faculty Department of Hematology

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-13
Primary Completion
2021-01-31
Completion
2021-01-31

Countries

  • Turkey (Türkiye)

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04104035 on ClinicalTrials.gov